T cell line passage can select for pre-existing neutralization-sensitive variants from the quasispecies of primary human immunodeficiency virus type-1 isolates

Virology

Volumn 359, Issue 1, 2007, Pages 92-104

  Quakkelaar, Esther D ^a   Beaumont, Tim ^a   van Nuenen, Ad C ^a   van Alphen, Floris P J ^a   Boeser Nunnink, Brigitte D M ^a   van 't Wout, Angélique B ^a   Schuitemaker, Hanneke ^a  

^a SANQUIN RESEARCH   (Netherlands)

Author keywords

Envelope glycoprotein; HIV 1; Neutralization; T cell line

Indexed keywords

ARTICLE; CELL CULTURE; CELL GROWTH; CELL LINE; CELL SELECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INOCULATION; MOLECULAR CLONING; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGENY; SPECIES DIVERSITY; T LYMPHOCYTE; VIRUS MUTATION; VIRUS NEUTRALIZATION;

ADAPTATION, PHYSIOLOGICAL; AMINO ACID SEQUENCE; BASE SEQUENCE; CELL LINE; HIV ANTIBODIES; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NEUTRALIZATION TESTS; PHYLOGENY; PROVIRUSES; RNA, VIRAL; SELECTION (GENETICS); SEQUENCE ALIGNMENT; T-LYMPHOCYTES; VARIATION (GENETICS);

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33846875181     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2006.09.021     Document Type: Article

References (38)

1. Beaumont T., Broersen S., van Nuenen A., Huisman H.G., De Roda Husman A.M., Heeney J.L., and Schuitemaker H. Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees. J. Virol. 74 (2000) 7699-7707
2. Beaumont T., van Nuenen A., Broersen S., Blattner W.A., Lukashov V.V., and Schuitemaker H. Reversal of HIV-1 IIIB towards a neutralization resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course. J. Virol. 75 (2001) 2246-2252
3. Beaumont T., Quakkelaar E., van Nuenen A., Pantophlet R., and Schuitemaker H. Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker. J. Virol. 78 (2004) 5651-5657
4. Beddows S., Lister S., Cheingsong R., Bruck C., and Weber J. Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4 using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals. J. Virol. 73 (1999) 1740-1745
5. Binley J.M., Trkola A., Ketas T., Schiller D., Clas B., Little S., Richman D., Hurley A., Markowitz M., and Moore J.P. The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection. J. Infect. Dis. 182 (2000) 945-949
6. Boom R., Sol C.J.A., Salimans M.M.M., Jansen C.L., Wertheim-van Dillen P.M.E., and Van der Noordaa J. A rapid and simple method for purification of nucleic acids. J. Clin. Microbiol. 28 (1991) 495-503
7. Broder C.C., Earl P.L., Long D., Abedon S.T., Moss B., and Doms R.W. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomeric-specific and-sensitive monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 11699-11703
8. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W.H., Sawyer L.S.W., Hendry R.M., Dunlop N., Nara P.L., Lamacchia M., Garratty E.M., Stiehm E.R., Bryson Y.J., Cao Y., Moore J.P., Ho D.D., and Barbas III C.F. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266 (1994) 1024-1027
9. Delwart E.L., Shpaer E.G., Louwagie J., McCutchan F.E., Grez M., Rubsamen-Waigmann H., and Mullins J.I. Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science 262 (1993) 1257-1261
10. Delwart E.L., Sheppard H.W., Walker B.D., Goudsmit J., and Mullins J.I. Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J. Virol. 68 (1994) 6672-6683
11. Derdeyn C.A., Decker J.M., Bibollet-Ruche F., Mokili J.L., Muldoon M., Denham S.A., Heil M.L., Kasolo F., Musonda R., Hahn B.H., Shaw G.M., Korber B.T., Allen S., and Hunter E. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303 (2004) 2019-2022
12. Frost S.D., Wrin T., Smith D.M., Kosakovsky Pond S.L., Liu Y., Paxinos E., Chappey C., Galovich J., Beauchaine J., Petropoulos C.J., Little S.J., and Richman D.D. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 18514-18519
13. Groenink M., Fouchier R.A.M., De Goede R.E.Y., De Wolf F., Cuypers H.T.M., Gruters R.A., Huisman H.G., and Tersmette M. Phenotypic heterogeneity in a panel of infectious molecular HIV-1 clones derived from a single individual. J. Virol. 65 (1991) 1968-1975
14. Groenink M., Moore J.P., Broersen S., and Schuitemaker H. Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type-1 variants upon soluble CD4 treatment. J. Virol. 69 (1995) 523-527
15. Hasegawa M., Kishino H., and Yano T. Dating of the human-ape splitting by a molecular clock of mitochondrial DNA. J. Mol. Evol. 22 (1985) 160-174
16. Kozak S.L., Platt E.J., Madani N., Ferro F.E., Peden K., and Kabat D. CD4, CXCR-4, and CCR5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J. Virol. 71 (1997) 873-882
17. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., and Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393 (1998) 648-659
18. Lapham C.K., Zaitseva M.B., Lee S., Romanstseva T., and Golding H. Fusion of monocytes and macrophages with HIV-1 correlates with biochemical properties of CXCR4 and CCR5. Nat. Med. 5 (1999) 303-308
19. McKnight A., Weiss R.A., Shotton C., Takeuchi Y., Hoshino H., and Clapham P.R. Change in tropism upon immune escape by human immunodeficiency virus. J. Virol. 69 (1995) 3167-3170
20. Moore J.P., and Ho D.D. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS 9 Suppl. A (1995) S117-S136
21. Moore J.P., Burkly L.C., Connor R.I., Cao Y., Tizard R., Ho D.D., and Fisher R.A. Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4. AIDS Res. Hum. Retroviruses 9 (1993) 529-539
22. Moore J.P., Cao Y., Qing L., Sattentau Q.J., Pyati J., Koduri R., Robinson J., Burton D.R., and Ho D.D. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69 (1995) 101-109
23. Moore P.L., Crooks E.T., Porter L., Zhu P., Cayanan C.S., Grise H., Corcoran P., Zwick M.B., Franti M., Morris L., Roux K.H., Burton D.R., and Binley J.M. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J. Virol. 80 (2006) 2515-2528
24. Ortiz G.M., Nixon D.F., Trkola A., Binley J., Jin X., Bonhoeffer S., Demoitie M.A., Donahoe S., Kuebler P.J., Kakimoto W.M., Ketas T., Clas B., Heymann J.J., Zhang L., Cao Y., Hurley A., Moore J.P., Ho D.D., and Markowitz M. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J. Clin. Invest. 104 (1999) 13-18
25. Pugach P., Kuhmann S.E., Taylor J., Marozsan A.J., Snyder A., Ketas T., Wolinsky S.M., Korber B.T., and Moore J.P. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. Virology 321 (2004) 8-22
26. Sauermann U., Schneider J., Mous J., Brunckhorst U., Schedel I., Jentsch K.D., and Hunsmann G. Molecular cloning and characterization of a German HIV-1 isolate. AIDS Res. Hum. Retroviruses 6 (1990) 813-823
27. Sawyer L.S.W., Wrin M.T., Crawford-Mikza L., Potts B., Wu Y., Weber P.A., Alfonso R.D., and Hanson C.V. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J. Virol. 68 (1994) 1342-1349
28. Stamatatos L., Werner A., and Cheng-Mayer C. Differential regulation of cellular tropism and sensitivity to soluble CD4 neutralization by the envelope gp120 of human immunodeficiency virus type 1. J. Virol. 68 (1994) 4973-4979
29. Sullivan N., Sun Y., Li J., Hofman W., and Sodroski J. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J. Virol. 69 (1995) 4413-4422
30. Swofford D.L. PAUP*. Phylogenetic Analysis Using Parsimony (*and Other Methods), version 4 (2002), Sinauer Associates, Sunderland, MA
31. Tersmette M., Winkel I.N., Groenink M., Gruters R.A., Spence P., Saman E., van der Groen G., Miedema F., and Huisman J.G. Detection and subtyping of HIV-1 isolates with a panel of characterized monoclonal antibodies to HIV-p24 gag. Virology 171 (1989) 149-155
32. Ugolini S., Mondor I., Parren P.W.H.I., Burton D.R., Tilley S.A., Klasse P.J., and Sattentau Q.J. Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell-line-adapted HIV-1 neutralization. J. Exp. Med. 186 (1997) 1287-1298
33. Upchurch D.A., Shankarappa R., and Mullins J.I. Position and degree of mismatches and the mobility of DNA heteroduplexes. Nucleic Acids Res. 28 (2000) E69
34. van Rij R.P., Blaak H., Visser J.A., Brouwer M., Rientsma R., Broersen S., De Roda Husman A.M., and Schuitemaker H. Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1. J. Clin. Invest. 106 (2000) 1039-1052
35. Van 't Wout A.B., Blaak H., Ran L.J., Brouwer M., Kuiken C., and Schuitemaker H. Evolution of syncytium inducing and non-syncytium inducing biological virus clones in relation to replication kinetics during the course of HIV-1 infection. J. Virol. 72 (1998) 5099-5107
36. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., and Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 422 (2003) 307-312
37. Xia X., and Xie Z. DAMBE: software package for data analysis in molecular biology and evolution. J. Heredity 92 (2001) 371-373
38. Zhang Y.-J., Fredriksson R., McKeating J.A., and Fenyö E.M. Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization. Virology 238 (1997) 254-264